Open AccessNanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
Author(s) -
Shuyang Sun,
Ziqiang Ding,
Xiaomei Yang,
Xiangxuan Zhao,
Minlong Zhao,
Guangyong Lin,
Chao Qu,
Shenxia Xie,
Aiqun Liu,
Shutao Yin,
Zhiping Xu,
Xiaoling Lü
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s297631
Subject(s) - monoclonal antibody , antibody , chimeric antigen receptor , medicine , drug delivery , cancer research , computational biology , immunology , immunotherapy , nanotechnology , materials science , biology , immune system
The development of monoclonal antibody treatments for successful tumor-targeted therapies took several decades. However, the efficacy of antibody-based therapy is still confined and desperately needs further improvement. Nanobodies are the recombinant variable domains of heavy-chain-only antibodies, with many unique properties such as small size (~15kDa), excellent solubility, superior stability, ease of manufacture, quick clearance from blood, and deep tissue penetration, which gain increasing acceptance as therapeutical tools and are considered also as building blocks for chimeric antigen receptors as well as for targeted drug delivery. Thus, one of the promising novel developments that may address the deficiency of monoclonal antibody-based therapies is the utilization of nanobodies. This article provides readers the significant factors that the structural and biochemical properties of nanobodies and the research progress on nanobodies in the fields of tumor treatment, as well as their application prospect.